Leveraging the active conformation of LFA-1 as a potential target for hematological malignancies

Current therapeutic strategies for non-Hodgkin's lymphomas (NHLs) and chronic lymphocytic leukemia (CLL) are limited by systemic toxicity, acquired resistance, and tumor-mediated immune suppression. To address these challenges, we introduce a novel nano-liposomal (NP) delivery system that exploits the overexpressed, open-active conformation of lymphocyte function-associated antigen-1 (LFA-1) on malignant hematopoietic cells. This approach facilitates the selective delivery of Wiskott-Aldrich syndrome (<i>WAS</i>)-specific short interfering RNA (siRNA) to lymphoma and leukemia cells. Compared to conventional therapies, our LFA-1-targeted NP system provides a significant advantage by enhancing cell-specific delivery, thereby minimizing off-target effects and potentially reducing systemic toxicity. LFA-1-targeted nanoparticles facilitated the precise delivery of <i>WAS</i> siRNA, resulting in potent inhibition of cytoskeletal-mediated oncogenesis. <i>In vitro</i> assays using patient-derived NHL and CLL cells confirmed significant reductions in proliferation, migration, and invasive capacity. These findings were further validated <i>in vivo</i>, where the targeted delivery system effectively suppressed tumor growth in a human B-NHL xenograft model. This targeted delivery strategy offers a precision approach to gene silencing in hematologic malignancies, potentially improving therapeutic efficacy and reducing adverse effects compared to current non-selective treatments for hematological malignancies, including B-NHL and CLL.